- Home
- EQ vs LITB Comparison
EQ vs LITB Comparison
Compare EQ & LITB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- LITB
- Stock Information
- Founded
- EQ 2017
- LITB 2007
- Country
- EQ United States
- LITB Singapore
- Employees
- EQ N/A
- LITB N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- LITB Catalog/Specialty Distribution
- Sector
- EQ Health Care
- LITB Consumer Discretionary
- Exchange
- EQ Nasdaq
- LITB Nasdaq
- Market Cap
- EQ 31.1M
- LITB 32.2M
- IPO Year
- EQ 2018
- LITB N/A
- Fundamental
- Price
- EQ $0.88
- LITB $1.03
- Analyst Decision
- EQ Buy
- LITB
- Analyst Count
- EQ 2
- LITB 0
- Target Price
- EQ $5.00
- LITB N/A
- AVG Volume (30 Days)
- EQ 2.2M
- LITB 17.5K
- Earning Date
- EQ 03-24-2025
- LITB 03-24-2025
- Dividend Yield
- EQ N/A
- LITB N/A
- EPS Growth
- EQ N/A
- LITB N/A
- EPS
- EQ N/A
- LITB N/A
- Revenue
- EQ $45,914,000.00
- LITB $333,093,000.00
- Revenue This Year
- EQ $4.77
- LITB N/A
- Revenue Next Year
- EQ N/A
- LITB N/A
- P/E Ratio
- EQ N/A
- LITB N/A
- Revenue Growth
- EQ 7.70
- LITB N/A
- 52 Week Low
- EQ $0.49
- LITB $0.91
- 52 Week High
- EQ $3.25
- LITB $6.00
- Technical
- Relative Strength Index (RSI)
- EQ 58.42
- LITB 40.52
- Support Level
- EQ $0.85
- LITB $0.97
- Resistance Level
- EQ $0.98
- LITB $1.18
- Average True Range (ATR)
- EQ 0.10
- LITB 0.11
- MACD
- EQ 0.01
- LITB 0.02
- Stochastic Oscillator
- EQ 62.50
- LITB 42.86
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
About LITB LightInTheBox Holding Co. Ltd.
LightInTheBox Holding Co Ltd is an online retail company delivering products directly to consumers across the world. It provides apparel products including customized, special occasion and fast fashion apparel products; and other general merchandise products, such as accessories and gadgets, home and garden products, electronics and communication devices, and other products. The company is engaged in product sales which consisted of online retailing of consumer products. It also provides services which consisted of the provision of logistic services to e-commerce retailers and small businesses. Geographically, it operates in Europe which is the key revenue driver, North America, and other countries.